• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience.

作者信息

Messina Sonia, Pane Marika, Sansone Valeria, Bruno Claudio, Catteruccia Michela, Vita Giuseppe, Palermo Concetta, Albamonte Emilio, Pedemonte Marina, Bertini Enrico, Binetti Luca, Mercuri Eugenio

机构信息

Department of Neurosciences, Psychiatry and Anaesthesiology and Centro Clinico Nemo, Messina, Italy.

Paediatric Neurology and Centro Clinico Nemo, Catholic University and Policlinico Gemelli, Rome, Italy.

出版信息

Neuromuscul Disord. 2017 Dec;27(12):1084-1086. doi: 10.1016/j.nmd.2017.09.006. Epub 2017 Sep 21.

DOI:10.1016/j.nmd.2017.09.006
PMID:29132728
Abstract
摘要

相似文献

1
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience.意大利针对1型脊髓性肌萎缩症使用诺西那生的扩大可及项目：一次成功经验的优点与缺陷
Neuromuscul Disord. 2017 Dec;27(12):1084-1086. doi: 10.1016/j.nmd.2017.09.006. Epub 2017 Sep 21.
2
Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.生存、运动功能和运动里程碑：AVXS-101 与 nusinersen 治疗 1 型脊髓性肌萎缩症婴儿的比较。
Adv Ther. 2019 May;36(5):1164-1176. doi: 10.1007/s12325-019-00923-8. Epub 2019 Mar 16.
3
Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.在德国扩展准入计划中接受 nusinersen 治疗的 1 型 SMA 患儿的评估。
J Neuromuscul Dis. 2018;5(2):135-143. doi: 10.3233/JND-180315.
4
[Spinal muscular atrophy treated with nusinersen].[用诺西那生治疗脊髓性肌萎缩症]
Ugeskr Laeger. 2019 Jan 7;181(2).
5
Nusinersen for SMA: expanded access programme.脊髓性肌萎缩症（SMA）用 nusinersen：拓展准入项目。
J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):937-942. doi: 10.1136/jnnp-2017-317412. Epub 2018 Mar 16.
6
Implementing a Global Expanded Access Program (EAP) for Infantile-Onset Spinal Muscular Atrophy (Type I): Understanding the Imperative, Impact and Challenges.实施婴儿型脊髓性肌萎缩症（I 型）全球扩展准入计划（EAP）：理解必要性、影响和挑战。
J Neuromuscul Dis. 2019;6(2):227-231. doi: 10.3233/JND-190387.
7
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.依库珠单抗治疗晚发性脊髓性肌萎缩症的疗效观察：一项随机、双盲、安慰剂对照 3 期试验
N Engl J Med. 2018 Feb 15;378(7):625-635. doi: 10.1056/NEJMoa1710504.
8
Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy.经颈椎穿刺术向脊髓性肌萎缩症患者递送 nusinersen。
Neurology. 2018 Aug 14;91(7):e620-e624. doi: 10.1212/WNL.0000000000006006. Epub 2018 Jul 13.
9
Intrathecal administration of Nusinersen in type 1 SMA: successful psychological program in a single Italian center.鞘内注射 Nusinersen 治疗 1 型 SMA：意大利单一中心的成功心理干预方案。
Neurol Sci. 2018 Nov;39(11):1961-1964. doi: 10.1007/s10072-018-3506-z. Epub 2018 Jul 25.
10
Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen.神经丝重链和 Tau 蛋白在接受 nusinersen 治疗的成年脊髓性肌萎缩症患者脑脊液中并未升高。
Int J Mol Sci. 2019 Oct 30;20(21):5397. doi: 10.3390/ijms20215397.

引用本文的文献

1
Spinal Muscular Atrophy Scoliosis in the Era of Background Therapies-A Review of the Literature.背景治疗时代的脊髓性肌萎缩症脊柱侧弯——文献综述
J Clin Med. 2024 Jun 14;13(12):3467. doi: 10.3390/jcm13123467.
2
Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy.巴西神经病学学会关于5q脊髓性肌萎缩症诊断、遗传咨询及疾病修饰疗法应用的共识
Arq Neuropsiquiatr. 2024 Jan;82(1):1-18. doi: 10.1055/s-0044-1779503. Epub 2024 Feb 5.
3
Neurodegenerative Diseases: New Hopes and Perspectives.
神经退行性疾病：新的希望和展望。
Curr Mol Med. 2024;24(8):1004-1032. doi: 10.2174/1566524023666230907093451.
4
An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy.利司扑兰用于 1 型或 2 型脊髓性肌萎缩症患者的扩展使用项目。
Ann Clin Transl Neurol. 2022 Jun;9(6):810-818. doi: 10.1002/acn3.51560. Epub 2022 May 14.
5
Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders.脊髓性肌萎缩症的治疗进展：对肌肉萎缩症和神经退行性疾病的展望
Neurol Res Pract. 2022 Jan 4;4(1):2. doi: 10.1186/s42466-021-00162-9.
6
Effect of the COVID-19 Pandemic on Children With SMA Receiving Nusinersen: What Is Missed and What Is Gained?2019年冠状病毒病大流行对接受诺西那生治疗的脊髓性肌萎缩症患儿的影响：失去了什么，又获得了什么？
Front Neurol. 2021 Sep 21;12:704928. doi: 10.3389/fneur.2021.704928. eCollection 2021.
7
Fondazione Telethon and Unione Italiana Lotta alla Distrofia Muscolare, a successful partnership for neuromuscular healthcare research of value for patients.特龙基金会和意大利肌肉萎缩症防治协会，在神经肌肉健康研究方面的成功合作，为患者带来了有价值的成果。
Orphanet J Rare Dis. 2021 Oct 2;16(1):408. doi: 10.1186/s13023-021-02047-1.
8
Posterior Spinal Correction and Fusion Surgery in Patients with Spinal Muscular Atrophy-Associated Scoliosis for Whom Treatment with Nusinersen Was Planned.计划接受诺西那生治疗的脊髓性肌萎缩症相关脊柱侧弯患者的后路脊柱矫正融合手术。
Spine Surg Relat Res. 2020 Aug 31;5(2):109-113. doi: 10.22603/ssrr.2020-0091. eCollection 2021.
9
Clinical Experience of Nusinersen in a Broad Spectrum of Spinal Muscular Atrophy: A Retrospective Study.诺西那生在广泛类型脊髓性肌萎缩症中的临床经验：一项回顾性研究
Ann Indian Acad Neurol. 2020 Nov-Dec;23(6):796-801. doi: 10.4103/aian.AIAN_524_20. Epub 2020 Oct 7.
10
Type I SMA "new natural history": long-term data in nusinersen-treated patients.I 型 SMA 的“新自然病史”：用 nusinersen 治疗的患者的长期数据。
Ann Clin Transl Neurol. 2021 Mar;8(3):548-557. doi: 10.1002/acn3.51276. Epub 2021 Feb 6.